MannKind Corp (MNKD) stock
MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30127% above fair value
$4.07+0.12 (+2.91%)
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
MannKind price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
MannKind's price to sales ratio was 3.3× on Nov 11, 2026, against 5.2× a year earlier. Over the last 5 years it ranged from 2.2× to 18.9×, with a median of 6.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.3× | −2.2 |
| 2025 | Dec 31, 2025 | 5.5× | −1.1 |
| 2024 | Dec 31, 2024 | 6.6× | +1.1 |
| 2023 | Dec 29, 2023 | 5.6× | −12.6 |
| 2022 | Dec 30, 2022 | 18.2× | +4.8 |
| 2021 | Dec 31, 2021 | 13.4× | +1.9 |
| 2020 | Dec 31, 2020 | 11.5× | +7.3 |
| 2019 | Dec 31, 2019 | 4.2× | −6.1 |
| 2018 | Dec 31, 2018 | 10.3× | −2.0 |
| 2017 | Dec 29, 2017 | 12.4× | +10.5 |
| 2016 | Dec 30, 2016 | 1.9× | – |
See a number that looks wrong?